[Effect of fructose-1,6-diphosphate and trental on the erythrocyte aggregating capacity in ischemic heart disease].
It was shown that fructose-1.6-diphosphate was capable of marked suppression of the aggregation power of the blood erythrocytes of patients with acute myocardial infarction and angina of effort. The antiaggregation effect of the drug was dose-related and enhanced with an increase in the time of its contact with erythrocytes. The antiaggregation effect of pentoxifylline was not of distinct dose-related nature. Its antiaggregation power did not considerably depend on the time of incubation with erythrocytes.
Badalian
G O
GO
Episkoposian
N G
NG
Amatuni
G V
GV
D000328:Adult; D000368:Aged; D000423:Alcian Blue / Q000494:pharmacology; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D005260:Female; D005635:Fructosediphosphates / Q000627:therapeutic use*; D006598:Hexosediphosphates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D010431:Pentoxifylline / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*
D005635:Fructosediphosphates; D006598:Hexosediphosphates; C029063:fructose-1,6-diphosphate; D013805:Theobromine; D000423:Alcian Blue; D010431:Pentoxifylline
Vliianie fruktozo-1,6-difosfata i trentala na agregatsionnuiu sposobnost' éritrotsitov krovi pri ishemicheskoĭ bolezni serdtsa.